Date of preparation: October 26, 2015

CURRICULUM VITAE

NAME: Louisa Balazs, M.D. Ph.D.

BIRTHPLACE:Romhany, Hungary / US Citizen by naturalization

GRADUATE/MEDICAL SCHOOL:

University Medical School of Pecs, Hungary, September 1970 – September 1976, M.D. degree, September 1976.

INTERNSHIP:

Neurology Psychiatry Hospital, University Medical School of Pecs, Hungary, September, 1975– February 1976.

RESIDENCY:

Anatomic Pathology, Department of Pathology, University Medical School of Pecs, Hungary, October 1976 – December 1980.

Anatomic Pathology, UTMG Department of Pathology, January 1993 – June 1995.

POSTGRADUATE TRAINING:

Ph.D. program in pathology-immunopathology, Department of Pathology, University Medical School of Pecs, Hungary, January 1982 – November 1887.

Malignant Lymphoma Reference Center of the European Organization for Research and Treatment of Cancer, University of Utrecht, The Netherlands, March 1983 – October 1983.

Diagnostic Molecular Pathology, unaccredited program, St.Jude’s Children’s Research Hospital, Memphis, TN, July 1995 – June 1996.

BOARD CERTIFICATION:

Anatomic Pathology, National Board of Medical Examiners of Hungary,

December 1980.

Anatomic Pathology, The American Board of Pathology, May 1996.

MEDICAL LICENSURE:

Tennessee, June 1996, active

Arkansas, February 1999, inactive

Mississippi, January 2002, active

SOCIETY AND MEMBERSHIPS:

United States and Canadian Academy of Pathology

College of American Pathologists

Memphis Pathology Society

UNIVERSITY APPOINTMENTS:

Chief of Clinical Services, Department of Pathology, University of Tennessee Health Science Center, Memphis, TN, December 2004 – present

Associate Professor of Pathology, tenure-track, Department of Pathology, University of Tennessee Health Science Center, Memphis, TN, December 2002 – present

Assistant Professor of Pathology, tenure-track, Department of Pathology, University of Tennessee Health Science Center, Memphis, TN,

December 2001 to 2002.

Assistant Professor of Pathology, part-time, non-tenure-track, Department of Pathology, University of Tennessee Health Science Center, Memphis, TN,

March 2001 – December 2001.

Adjunct Assistant Professor of Pathology, Department of Pathology, University of Tennessee Health Science Center, Memphis, TN, July 1996 – March 2001.

HOSPITAL APPOINTMENTS:

VA Hospital, Memphis, active staff, February 2009 – February 2011.

The Regional Medical Center of Memphis, active staff, July 1996-present

UTMG, Bowld Hospital, active staff, July 1996- 2005

TEACHING EXPERIENCE:

Laboratory course to medical students, 1993 -1999, 32 hours per semester, 20 students per class, College of Medicine, UT Memphis

Elective classes to medical students, 1999 – 2002, 6 hours per semester 10 students per class, College of Medicine, UT Memphis

M2 Pathology Lectures, 2001 – 2011, 2 hours per year, 170 students, College of Medicine, UT Memphis.

Gross pathology conference to residents, Department of Pathology, UT Memphis 1996 – present, 12 hours per year, 14 residents

Genitourinary Pathology conference to resident, Department of Urology, UT Memphis, 1999 – 2001, 15 residents, 2 hours per year

Tumor Board, Department of Surgery, 1997 – 2003. 24 hours per year, 50 medical students and residents

Tumor Treatment Planning conferences, Department of Otolaryngology, UT Memphis, 1997 – 2001. 10 hours per year, 15 residents

CPC conferences, Department of Medicine, UT Memphis, 2001 – 2008, 12 hours per year, 20 residents

Lung Conferences, Department of Medicine, Division of Pulmonology, 50 hours per year, 2004 – 20010.

CPC Cardiology Conference, 10 hours per year, 2006 – 2008.

COMMITTEES AND OFFICES HELD:

Compliance officer, Department of Pathology, 1999 – 2004.

Director of Hospital Autopsy Services, UT Bowld Hospital and Regional Medical Center, Memphis, 2001- 2002.

Chief of clinical services in Anatomic Pathology, UTHSC, Department of Pathology and Laboratory Medicine, 2002 – recent

Medical Director of Laboratory Corporation of America, Northern Mississippi and Memphis regions, 2003 – March 2014.

University Pathology Group, Board Member, 2004 to present

COMMITTEES AND OFFICES HELD (continued):

University of Tennessee, Memphis, Pathology Residency Committee

Dean’s Faculty Advisory Committee

RESEARCH AND OTHER EXTERNAL SUPPORT:

UTMG Research Grant, 1995 – 1996

ROLE: Co-investigator

NIH USPHS HL 61469, 1998 – 2002

ROLE: Collaborator

Department of Defense, Breast Cancer Program, BC 990290, 2000 – 2003

ROLE: Collaborator

NIH USPHS HL 61469, 15% funded effort, competing renewal, 2002 – 2007

ROLE: Co-investigator

1 RC2 AI087550-01 10/01/09 - 09/30/12,4.8 calendar months, $1,074,746

Preclinical Development of a GI Radiation Countermeasure

NIH/NIAID

The goal of the project is to complete the testing of a radiomitigator in non-human primates.

ROLE: Co-investigator

5 R01 CA092160-09 08/01/01 - 07/31/11 1.2 calendar months $277,340

Ligand recognition by phospholipid growth factor receptors

The goals of this project was to develop and validate a refined computational model for the interaction of SPP with the EDG1 receptor, identify residues conferring specificity for sphingolipids in the EDG3/5/6/8 receptor subfamily, and to identify residues involved in glycerolipid recognition in the EDG2/4/7 receptor subfamily

ROLE: Collaborator

AI-107331 IND-Enabling preclinical development of a new radiomitigator.

2013-2014, $13,643 + benefits (10% effort).

ROLE: Collaborator

AWARDS:

Residents’ Teaching Award, 2001/2002 academic year.

LIST OF PUBLICATIONS:

  1. Balogh, A., Shimizu, Y., Lee, S-C., Norman, D.,D.,Gangwar, R., Bavaria, M., Moon, C.,S., Shukla., Rao, R., Ray, R., Naren, A., Banerje, S., Miller, D.,D., Balazs, L., pelus, L. and Tigyi, G. J.:The autotoxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair. 2015 CellSignal. 27:1751-1762 [Epub ahead os print] PMID 26027517.
  2. Deng, W., Kimura, Y., Gududuru, V., W., Balogh, A., Szabo, E., Emmons-Thompson, K., Yates, C., R., Balazs, L., Johnson,L.,R.,Miller, D., D.,Strobos, J., McCool, W., S., and Tigyi, G., J.: Mitigation of the hematopoietic and gastrointestinalacute radiation syndrome by octadecylthiophosphate a smallmolecule mimic of lysophosphatidic acid.2015Radiation Res. 183:465-475. Epub 2015 March 25. PMID: 25807318.
  3. Patil, R., Szabo, E., Fells, J., I., Balogh, A., Kim,K., G., Fujiwara, Y., Norman,D., B., Lee, S-C., Balazs, L., Thomas, F., Byrne, G., I., Miller, D., D., Tigyi, G., J.: Protection against the gastrointestinal and hematopoietic acute radiation syndrome by a novel LPA2 receptor-specific non-lipid agonist. 2015. Chem. Biol. (Cell Press) 22:1-11. PMID: 25619933.
  4. Lee, S., F., Fujiwara,Y., yue, J., Wang, Y., Tsukahara, R., Szabo, E., Patil., R., Banerjee, < S., Miller, D., D., Balazs, L., Ghosh, M., C., Waters, C., M., Oravecz, T. and Tigyi, G., J.: Autotoxin, lysophosphatidic acid receptors 1 and 5 exert different fuctions in tumor cells versus the host tissue microenviroment in melanoma invasion and metastasis. 2015. Mol. Cancer Res.: 174-185. PMID 25158955.
  5. Chen, Z., Wu, J., Yang, C., Fan, P., Balazs, L., Jiao Y., Lu, M., Gu, W., Li, C., Pfeffer, L., M., Tigyi, G., J., Yue, J.: DiGeorge syndrome critical region 8 (DGCR8) –mediated miRNA biogenesis is essential for vascular smooth muscle cell development in mice. 2012. J. Biol. Chem. 287:19018-28. Apr. 17. [Epub ahead of print] PMID: 22511778.
  6. Gotoh, M., Fujiware, Y., Yue, J., Liu, J., Fee, S., Fells, J., Uchiyama, A., Murakami-murofushi, K., Kennel, S., Wall, J., Patil, R., Gupta, R., Balazs, L., Miller, D., D., and Tigyi, G., J.: Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. 2012. Biochem. Soc. Transact., 40:31-36. PMID:22260662.
  1. Makena P, Gorantla VK, Ghosh MC, Bezawada LB, Luellen CL, Parthasaraty K, Balazs L, Waters, C and Sinclair, S: Lung injury caused by high

tidal volume mechanical ventilation and hyperoxia is dependent on oxidant- mediated c-Jun NH2-terminal kinase (JNK) activation (2011) J. AppliedPhysiology PMID 21799126.

  1. Makena SP, Gorantla VK, Gosh MC, Bezawada L, Kandasamy K, Balazs L,

Thompson KE, Parthasaraty K, Ichijo H, Waters C and Sinclair S: Deletion of

apoptosis signal regulating Kinase-1 prevents ventilator induced lung injury:

American J of Respiratory Cell and Molecular Biology, 11/2011

  1. Yaoquian Pan, Balazs L, Tigyi G and Yunming Yue: Conditional deletion of dicer in vascular smooth muscle cells leads to the developmental delay and embryonic mortality (2011) Biochemical and Biophysical ResearchCommunication, PMID 21371421
  2. Liu X, Li F, Sun SQ, Thangavel M, Kaminsky J, Balazs L, Ostrom RS. Fibroblast-specific expression of AC6 enhances beta-adrenergic and prostacyclin signaling and blunts bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. (2010) 298(6):L819-29. Epub 2010 Mar 26.PMID: 20348281.
  3. Tsukahara T, Tsukahara R, Fujiwara Y, Yue J, Cheng Y, Guo H, Bolen A, Zhang C, Balazs L, Re F, Du G, Frohman MA, Baker DL, Parrill AL, Uchiyama A, Kobayashi T, Murakami-Murofushi K, Tigyi G. Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic phosphatidic acid. Mol. Cell. 2010 Aug 13;39(3):421-32.PMID: 20705243
  4. Makena PS, Luellen CL, Balazs L, Ghosh MC, Parthasarathi K, Waters CM, Sinclair SE. Pre-exposure to hyperoxia causes increased lung injury and epithelial apoptosis in mice ventilated with high tidal volumes.(2010) Am JPhysiol Lung Cell Mol Physiol. Nov; 299(5):L711-9. Epub 2010 Sep 10.PMID: 20833778
  5. Cheng Y, Makarova N, Tsukahara, R, Guo H E S, Farrar P, Balazs, L, Zhang C, Tigyi G: Lysophosphatidic Acid-induced Arterial Wall Remodeling: Requirement of PPAR but Not LPA1 or LPA2 GPCR. Cell Signal. 21(12):1874-84. Epub 2009 Aug 23. PMID: 19709640
  6. Zafar N, Balazs L, Benstein BD. Synchronous high-grade squamous intraepithelial lesion and adenocarcinoma in situ of cervix in a young woman presenting with hyperchromatic crowded groups in the cervical cytology specimen: report of a case. (2008) Diagn Cytopathol. 36(11):823-6.PMID: 18831021
  7. Deng W, Shuyu E, Tsukahara R, Valentine WJ, Durgam G, Gududuru V, Balazs L, Manickam V, Arsura M, VanMiddlesworth L, Johnson LR, Parrill AL, Miller DD, Tigyi G.The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology, 2007 May;132(5):1834-51.
  8. Deng WES, Tsukahara R, Valentine W, Durgam G, Gududuru V, Balazs L, VanMiddlesworth, L., Johnson, L.R., Manickam, V., Arsura, M., Parrill, A.L., Miller, D.D. and Tigyi, G. (2007) The LPA2 Receptor is Required for Protection Against Radiation-Induced Intestinal Injury. Gastroenterology 132(5):1834-51. PMID: 17484878
  9. Yue J, Yokoyama K, Balazs L, Baker DL, Smalley D, Pilquil C, Brindley DN, Tigyi G. Mice with transgenic overexpression of lipid phosphate phosphatase-1 display multiple organotypic deficits without alteration in circulating lysophosphatidate level. Cell Signal. 2004 Mar;16(3):385-99.
  10. Yue J, Yokoyama K, Balazs L, Baker DL, Smalley D, Pilquil C, Brindley DN, Tigyi G. (2004) Mice with transgenic overexpression of lipid phosphate phosphatase-1 display multiple organotypic deficits without alteration in circulating lysophosphatidate level. Cell Signal. Mar;16(3):385-99.PMID: 14687668
  11. Zhang C, Baker DL, Yasuda S, Makarova N, Balazs L, Johnson, LR. Marathe, GK, McIntyre TM, Xu Y, Prestwich GD, Byun H-S, Bittman R, and Tigyi G: (2004) Lysophosphatidic Acid Induces Neointima Formation Through PPAR Activation J.Exp. Med. 199:763-774. PMID: 15007093
  12. Wang C, McCarty IM, Balazs L, Li Y, Steiner MS. Cloning a cDNA encoding an alternatively spliced protein of BRCA2-associated factor 35. (2002) Biochem Biophys Res Commun. Jul 5;295(1):129-35.PMID: 12083779
  13. Wang C, McCarty IM, Balazs L, Li Y, Steiner MS. A prostate-derived cDNA that is mapped to human chromosome 19 encodes a novel protein. (2002) Biochem Biophys Res Commun. Aug 16;296(2):281-7.PMID: 12163014
  14. Wang C, McCarty IM, Balazs L, Li Y, Steiner MS. Immunohistological detection of BRAF25 in human prostate tumor and cancer specimens. (2002) Biochem Biophys Res Commun. Jul 5;295(1):136-41.PMID: 12083780
  15. Deng W, Balazs L, Wang DA, Van Middlesworth L, Tigyi G, Johnson LR. Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis. Gastroenterology. 2002 Jul;123(1):206-16.
  16. Balazs L, Okolicany J, Ferrebee M, Tolley B, Tigyi G. Topical application of the phospholipid growth factor lysophosphatidic acid promotes wound healing in vivo. Am J Physiol Regul Integr Comp Physiol. 2001 Feb;280(2):R466-72.
  17. Balazs L, Okolicany J, Ferrebee M, Tigyi G. Topical application of LPA accelerates wound healing. Ann N Y Acad Sci. 2000 Apr;905:270-3.
  18. Kane JR, Head, DR, Balazs L, Hulsof MG, Motreoni, TA, Behm F, Shurtleff SA, Downing JR: Molecular analysis of the PML/RAR alpha chimeric gene in pediatric acute promyelocytic leukemia. Leukemia. 1996 Aug;10(8):1296-302.
  19. Balazs L, Leon M. Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem Res. 1994 Sep;19(9):1131-7.
  20. Sharma BS, Mhaskar S, Balazs L, Siaw M. Immunomodulatory activity of a novel nucleoside, 7-thia-8-oxoguanosine: I. Activation of natural killer cells in mice. Immunopharmacol Immunotoxicol. 1992;14(1-2):1-19.
  21. Sharma BS, Mhaskar S, Balazs L, Jin A, Smee DF. Immunomodulatory activity of a novel nucleoside, 7-thia-8-oxoguanosine. II. Characterization of induced effector cells and the mechanism of induction. ImmunopharmacolImmunotoxicol. 1992;14(1-2):21-38.
  22. Sharma BS, Balazs L, Jin A, Jolley WB, Robins RK. Successful immunotherapy of murine melanoma metastases with 7-thia-8-oxoguanosine. Clin Exp Metastasis. 1991 Sep-Oct;9(5):429-39.
  23. Sharma BS, Balazs L, Jin A, Wang JC, Jolley WB, Robins RK. Potentiation of the efficacy of murine L1210 leukemia vaccine by a novel immunostimulator 7-thia-8-oxoguanosine: increased survival after immunization with vaccine plus 7-thia-8-oxoguanosine. Cancer Immunol Immunother. 1991;33(2):109-14.
  24. Balázs L: Immunohistology of Hodgkin's disease. Use of monoclonal antibodies in the analysis of the pathomorphology of Hodgkin's disease Morphol.Igazsagugyi Orv. Sz. 1990 Jul;30(3):182-90.
  25. Balázs L: The incidence of Hodgkin's disease: characteristics of its appearance, histological types Morphol Igazsagugyi Orv Sz. 1990 Apr;30(2):129-33
  26. Nagy J, Scott H, Brandtzaeg P, Rumi G, Csermely L, Burger T, Balázs L. Antibodies against nutritional antigens in IgA nephropathy. Orv. Hetil. 1989 Jan 1;130(1):19-22.
  27. Pap T, Agoston M, Kalász V, Kuch B, Balázs L, Burger T. Secondary plasma cell leukemia (a multi-parameter study)] Orv. Hetil. 1987 Jan 25;128(4):197-201.
  28. Herendi E, Balázs L. Morphologic consequences of prenatal anoxic damage. Morphol Igazsagugyi Orv Sz. 1987 Jan. 27(1):34-9.
  29. Burger T, Balázs L, Schmelczer M, Molnár L, Török L, Fábián G.Lymphocyte subpopulations and immunoglobulins in idiopathic thrombocytopenic purpura (ITP). Acta Med Hung. 1987. 44(2-3):243-56.
  30. Burger T, Balázs L, Schmelczer M, Molnár L, Török L, Fábián G. Lymphocyte subpopulations and immunoglobulins in idiopathic thrombocytopenic purpura. Orv Hetil. 1986 Feb 16;127(7):379-84.
  31. Herendi E, Balázs L: Perinatal subependymal cerebral hemorrhages (pathomorphological characteristics). Orv Hetil.
  32. 1985 Jun 2;126(22):1339-42.
  33. István L, Balázs L, Brittig F, Pócza K, Szentcsiki M, Brenner F. Incidence of highly malignant immunoblastic non-Hodgkin lymphoma in patients with Hodgkin's disease in remission. Orv Hetil. 1985 May 26;126(21):1267-72.
  34. Szekeres-Bartho J, Hadnagy J, Csernus V, Balázs L, Magyarlaki T, Pacsa AS. Increased NK activity is responsible for higher cytotoxicity to HEF cells by lymphocytes of women with threatened preterm delivery. Am J Reprod Immunol Microbiol. 1985 Jan;7(1):22-6.
  35. Kádas I, Balázs L, Pár A, Barna K. Angiosarcoma of the liver following brief arsenic therapy. Zentralbl Allg Pathol. 1985;130(6):539-43
  36. Tigyi GJ, Balázs L, Monostori E, Andó I. Isolation of the human myelin basic protein by immunoaffinity chromatography with a monoclonal antibody. Mol Immunol. 1984 Oct;21(10):889-94.
  37. Kádas I, Balázs L, Pár A, Barna K. Angiosarcoma of the liver after short-term arsenic therapy Morphol Igazsagugyi Orv Sz. 1984 Apr;24(2):136-40.
  38. Balázs L, Mátyás G. Immunoperoxidase reaction. Factors enhancing optimal results. Morphol Igazsagugyi Orv Sz. 1983. Oct;23(4):301-7.
  39. Kelényi G, Balázs L. A new trend in pathology: the immunoperoxidase technic. Orv Hetil. 1983 Jul 10;124(28):1675-9.
  40. Balázs L: Detection of intracytoplasmic immunoglobulins. Morphol IgazsagugyiOrv Sz. 1983 Apr;23(2):134-42.
  41. Balázs L, Nagy VJ, Szakács I. Pathomorphology and clinico-pathology of Lennert lymphoma. Morphol Igazsagugyi Orv Sz. 1981 Oct;21(4):273-7.
  42. Török I, Tiszai A, Boros I, Balázs L, Kelényi G. Angioimmunoblastic lymphadenopathy and Hodgkin's disease. Morphol Igazsagugyi Orv Sz. 1981 Apr;21(2):107-12.
  43. Balázs L: Intracellular immunoglobulins in lymphogranulomatosis. Morphol Igazsagugyi Orv Sz. 1981 Jan;21(1):59-63.
  44. Balázs L, Várbiró M, Pap T, Kelényi G. Activities of the Malignant Lymphoma Reference Center. Orv Hetil. 1980 Jul 20;121(29):1795-6. Hungarian. PMID: 7454291
  45. Balázs L, István L, Marton E, Kádas L, Kelényi G. Nodular splenic immunocytoma. Acta Med Acad Sci Hung. 1980;37(3):253-60.
  46. Balázs L, Kelenyi G. Intracellular immunoglobulins in lymphogranulomatosis. Folia Haematol Int Mag Klin Morphol Blutforsch. 1980;107(4):621-7.
  47. Balázs L, István L, Marton E, Kádas L, Kelényi G. Splenic nodular immunocytoma. Orv Hetil. 1979 Oct;120(41):2497-500.
  48. Varga SM, Szabó I, Balázs L: Hyperacute encephalomyelitis following lyssa vaccination. Morphol Igazsagugyi Orv Sz. 1979 Jan;19(1):27-31.

1